Nice, FRANCE - 17 Jun `19Glisodin with UVB

Official Title: Gastroprotected Superoxide Dismutase in Combination With UVB vs Placebo and UVB for Treating Vitiligo. A Randomized Double Blind Placebo Controlled Monocentric Study

In Brief: Glisodin 4 pills a day (1000mg) for 3 months then 2 pills a day (500 mg) for 3 months

Ages Eligible:  18 Years and older

Start Date: June 17, 2019

Completion Date (estimated): November 2, 2020

Status: Active, recruiting

Study ID from ClinicalTrials.gov: NCT03941808

Location: Centre Hospitalier Universitaire de Nice at Nice, Alpes-Maritime, France, 06001

Contact: To learn more about this study, you or your doctor may contact Passeron Thierry, PhD by phone +33492034688 or email passeron.t@chu-nice.fr. Please refer to this study by its NCT number.         

FAQOther Questions

  • What is vitiligo?

     Vitiligo (pronounced vit-ill-EYE-go) is a generally unpredictable skin disease that causes a gradual loss of skin color and overlying hair on different parts of the body. Cont...

  • I have vitiligo: will my children have vitiligo, too?

    Children born to parents who both have the disorder are more likely to develop vitiligo. However, most children will not get vitiligo even if one parent has it. In children with...

  • Isn't it just a cosmetic disorder?

    Contrary to popular belief, vitiligo is not a cosmetic disorder but a systemic disease affecting the largest body organ and other vital systems, with multiple comorbidities. Fo...